{"contentid": 488227, "importid": NaN, "name": "Sobi secures UK reimbursement nod for Kineret", "introduction": "Three years after launching in the UK, Swedish Orphan Biovitrum's Kineret (anakinra) has secured a positive reimbursement decision from the country\u00e2\u0080\u0099s health technology assessor.", "content": "<p>Three years after launching in the UK, Swedish Orphan Biovitrum's (STO: SOBI) Kineret (anakinra) has secured a positive reimbursement decision from the country&rsquo;s health technology assessor.</p>\n<p>The National Institute for Health and Care Excellence (NICE) has recommended Kineret as a biologic option for Still&rsquo;s disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still&rsquo;s Disease (AOSD).</p>\n<p>The treatment has been available since 2018, following regulatory approval from the European Medicines Agency, but until now limited funding has been in place for its use.<br /> <br />The decision unlocks funding for the therapy&rsquo;s use as a second-line option in sJIA, and a third-line option for people with AOSD.</p>\n<h2>Kineret development</h2>\n<p>Discovered and developed by US biotech giant Amgen (Nasdaq: AMGN), the interleukin (IL)-1 antagonist was first cleared in the USA in 2001 for rheumatoid arthritis, and was licensed to Sobi in 2008.</p>\n<p>An updated agreement in 2013 gave the Swedish company full rights to develop and commercialize the therapy for all therapeutic indications.</p>\n<p>Globally, the product generated around $230 million in revenue for the firm last year.</p>\n<p>Commenting on the reimbursement decision, Athimalaipet Ramanan, consultant pediatric rheumatologist at Bristol Royal Hospital for Children, said Kineret &ldquo;offers an effective, therapeutic option for a disease which can be associated with significant morbidity among patients.&rdquo;</p>\n<p>Paul Brogan, of Great Ormond Street Hospital Institute for Child Health, commented: &ldquo;This final NICE guidance endorses that clinicians have the flexibility to use anakinra earlier in the patient pathway, as a first-line biologic therapy, which is something specialists in this area welcome and brings us closer to quicker disease control that would prevent progressive joint and systemic damage.&rdquo;</p>", "date": "2021-04-01 10:47:00", "meta_title": NaN, "meta_keywords": "Kineret, reimbursement, decision, health, Swedish, anakinra, option, disease, Sobi, secures, Biovitrum, SOBI, Orphan, secured, positive, launching, years", "meta_description": "Three years after launching in the UK, Swedish Orphan Biovitrum's (STO: SOBI) Kineret (anakinra) has secured a positive reimbursement decision from the country\u00e2\u0080\u0099", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-01 10:46:15", "updated": "2021-04-01 10:57:15", "access": NaN, "url": "https://www.thepharmaletter.com/article/sobi-secures-uk-reimbursement-nod-for-kineret", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "sobi-logo-big.jpg", "image2id": "sobi-logo-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Anti-Arthritics/Rheumatics, Rare diseases", "topic_tag": "Focus On, Pricing, reimbursement and access", "geography_tag": "Sweden, UK", "company_tag": "Swedish Orphan Biovitrum", "drug_tag": "Kineret", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-01 10:47:00"}